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in any medium, provided the original work is properly citePigment cells and neuronal cells both are derived from the neural crest. Here, we
describe the Pit-Oct-Unc (POU) domain transcription factor Brn3a, normally
involved in neuronal development, to be frequently expressed in melanoma,
but not in melanocytes and nevi. RNAi-mediated silencing of Brn3a strongly
reduced the viability ofmelanoma cell lines and decreased tumour growth in vivo.
In melanoma cell lines, inhibition of Brn3a caused DNA double-strand breaks as
evidenced by Mre11/Rad50-containing nuclear foci. Activated DNA damage
signalling caused stabilization of the tumour suppressor p53, which resulted
in cell cycle arrest and apoptosis. When Brn3a was ectopically expressed in
primary melanocytes and fibroblasts, anchorage-independent growth was
increased. In tumourigenic melanocytes and fibroblasts, Brn3a accelerated
tumour growth in vivo. Furthermore, Brn3a cooperated with proliferation path-
ways such as oncogenic BRAF, by reducing oncogene-induced senescence in non-
malignant melanocytes. Together, these results identify Brn3a as a new factor in
melanoma that is essential for melanoma cell survival and that promotes
melanocytic transformation and tumourigenesis.wig-Maximilian Uni-
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d.INTRODUCTION
Characteristic properties of cancer cells, such as increased cell
proliferation, survival or cell migration, are also essential for
embryonic development. Re-expression of molecules involved
in embryogenesis can confer malignant properties to tumour
cells. Lineage-specific re-expression of such factors can
characterize certain cancer types and is of potential therapeutic
value.
Melanoma, one of the deadliest types of skin cancer, derives
from melanocytes. Melanocytes and neuronal cells both
originate from the same precursor cells located in the neural
crest. During embryonic development, multipotent neural crest
cells become progressively restricted to specific sub-lineages,
including neuronal cell types, endocrine cells and melanocytic
cells (Crane & Trainor, 2006). In neuroectodermal tumours as
well as in melanoma, a deregulated expression of neuronal
factors normally expressed in neural crest cells may contributes is an open access article under
se, distribution and reproduction
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920to malignancy (Herlyn et al, 2000; Pla et al, 2001; Truzzi et al,
2008).
The transcription factors of the Pit-Oct-Unc (POU) domain
family play important roles in the development of neuronal
cells. Brn2 (POU3F2) is required for the development of
endocrine tissues and neurosecretory neurons (Schonemann
et al, 1995), and tumour-promoting effects have been described
(Carreira et al, 2005; Cook & Sturm, 2008; Goodall et al, 2008).
Brn3a (POU4F1) is expressed in proliferating precursor cells of
the peripheral nervous system originating from the neural crest
(Fedtsova & Turner, 1995). In adults, Brn3a expression is
primarily restricted to neuronal tissues, i.e. sensory ganglia and
parts of the central nervous system (Collum et al, 1992; He et al,
1989). More recently, Brn3a expression was detected also in
other tissues (Budhram-Mahadeo et al, 2001, 1999b). Brn3a-
deficient mice display apoptosis of certain sensory neurons
(McEvilly et al, 1996; Xiang et al, 1996). Tumour-promoting
potential of Brn3a has been proposed, because of this
antiapoptotic role in neuronal cells and a structural similarity
to c-myc (Ensor et al, 2001; Gerrero et al, 1993). Brn3a can
activate transcription of antiapoptotic Bcl-2 and Bcl-xL by
binding to their respective promoters (Ensor et al, 2001; Smith
et al, 1998, 2001). Furthermore, Brn3a can interact with the
tumour suppressor p53 and this protein–protein interaction
seems to modulate the activity of both factors (Budhram-
Mahadeo et al, 1999a; Hudson et al, 2005).
Here, we demonstrate expression of Brn3a in melanoma.
Brn3a is of high relevance for melanoma cell proliferation and
survival. Furthermore, in non-malignant cells expression of
Brn3a promotes malignant transformation.RESULTS
Brn3a is expressed in human melanoma, but not in
melanocytes and other non-malignant skin cells
Brn3a expression was analysed in human melanoma cell lines
and in non-malignant skin cells. More than 75% of melanoma
cell lines (10 of 13) expressed highly increased levels of Brn3a
mRNA compared to melanocytes, fibroblasts and keratinocytes
(Fig 1A). At the protein level, Brn3a was increased in almost all
melanoma cell lines (11 of 12) and was not associated with a
specific progression stage (Fig 1B). In WM9 and WM278 cells,
Brn3a protein was clearly detectable despite low mRNA levels.
The regulation of Brn3a in these cells is not entirely clear. Only
one cell line (WM3211) was found to express low amounts of
Brn3a both on mRNA and on protein level. In human tissue,
Brn3a was detected in 55% (49 of 89) primary melanoma
samples (Fig 1C). The intensity of staining ranged from strong to
rather weak, and both large tumour areas with homogenous
staining as well as small Brn3a-positive areas were observed.
Strong activity of a Brn3a luciferase reporter was observed in
Brn3a-expressing melanoma cell lines (1205Lu, WM1158,
WM1232), but not in WM3211 cells with low Brn3a levels
(Supporting Information Fig S1A) confirming transcriptional
activity of Brn3a in melanoma. Successful transfection of siRNA
and expression vectors was confirmed in this cell line, which 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.therefore was used as negative control in subsequent experi-
ments (Supporting Information Fig S1B).
Inhibition of Brn3a reduces melanoma cell viability and leads
to reduced tumour growth in vivo
The functional relevance of Brn3a in melanoma was studied
using RNAi. Two siRNAs targeting Brn3a were used in order to
control for non-specific effects. Both efficiently inhibited Brn3a
expression (Fig 2A) and transcriptional activity (Supporting
Information Fig S1C). Silencing of Brn3a resulted in a reduced
cell number and altered morphology (Fig 2B). Reduced cell
viability (more than 50%) was confirmed in several Brn3a-
expressing melanoma cell lines, but not in WM3211 cells (low
Brn3a levels) or primary melanocytes (Fig 2C). In general,
siRNA transfection into melanocytes was successful but less
reliable compared to melanoma cells. Therefore, it cannot be
excluded that low inhibition efficacy is one reason for unaltered
melanocyte viability. Next, we tested whether Brn3a inhibition
affects tumour growth in vivo. Nude mice carrying palpable
subcutaneous tumours were systemically treated with siRNA.
Brn3a inhibition significantly delayed tumour growth (Fig 2D).
Brn3a mRNA in tumours was reduced by around 50%,
indicating successful targeting of Brn3a (Fig 2E).
Brn3a inhibition induces cell cycle arrest followed by
apoptosis in melanoma cells
To explore the cause of reduced cell viability, cell cycle analysis
was performed. A striking loss of 1205Lu cells in the S phase
became apparent 48 h after Brn3a inhibition (Fig 3A). Similarly,
a loss of cells in the S phase and an increase in the G1 phase was
detected in WM1158 and WM1232 cells (Fig 3B), but not in
WM3211 cells (Fig 3C). To further control that cell cycle arrest is
indeed due to loss of Brn3a, we generatedmutant Brn3a variants
that contain silent base pair mismatches within the siRNA
binding site (Supporting Information Fig S1D). Whereas Brn3a
inhibition was still present upon overexpression of wild-type
Brn3a, ectopic expression of the respective mutant form
compensated for endogenous Brn3a losses induced by the
corresponding siRNA (Supporting Information Fig S1E). Cell
cycle analysis revealed that melanoma cells were rescued from
Brn3a siRNA-mediated cell cycle arrest when the corresponding
mutant Brn3a variant was expressed (Supporting Information
Fig S1F). This indicates that the cell cycle arrest was indeed due
to loss of Brn3a.
Later (72 h), a sub-G1 fraction suggested that these cells
undergo apoptosis (Fig 3A). This was confirmed by Annexin V
staining showing an increase in apoptotic cells to around 20%
(Fig 3D). Again, apoptosis was not induced in WM3211 cells
(Fig 3D) and in melanocytes. Caspase 3 and 9, but not caspase 8,
were cleaved indicating activation of the mitochondrial
apoptosis pathway (Fig 3E). Likewise, release of cytochrome
c into the cytosol was observed (Supporting Information Fig S2A).
In addition, antiapoptotic Bcl-2, Bcl-xL and Bcl-w levels
were reduced (Fig 3F) and proapoptotic Bax and Bak levels
enhanced (Supporting Information Fig S2B). On transcript
level, Bcl-2 and Bcl-xL were reported to be transcriptionally
upregulated by Brn3a (Smith et al, 1998, 2001), however, inEMBO Mol Med (2013) 5, 919–934
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Figure 1. Brn3a is expressed in human melanoma, but not in melanocytes and other non-malignant skin cells.
A. Brn3a mRNA levels in primary human skin cells of different donors and human melanoma cell lines (RGP, radial growth phase; VGP, vertical growth phase).
Mean SD is shown. The mutation status of BRAF/NRAS and of p53 is indicated (N: NRAS mutated, B: BRAF mutated, WT: wild-type, MT: p53 mutated,
ND: mutation status not determined); p<0.05 versus all melanocyte donors, t-test, n¼3 per group; n.s.: not significant (p> 0.05).
B. Brn3a protein levels were determined by immunoblotting using an antibody that detects full-length Brn3a isoform (47 kDa). 1205Lu cells were included on
each blot to ensure equal film exposure (not shown). Representative blots (n¼ 3) are shown.
C. Specimens of human primary melanomas were analysed for Brn3a expression in situ by immunohistochemistry. Four representative samples are shown. Red
staining represents Brn3a, brownish colour pigment. Scale bar: 200mm. The lower-right insert depicts a fourfold magnification of the respective area.
EMBO Mol Med (2013) 5, 919–934  2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 921
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Figure 2. Inhibition of Brn3a reduces melanoma cell viability and leads to reduced tumour growth in vivo.
A. 1205Lu melanoma cells were transfected with two siRNAs specific for Brn3a (Brn3a 1 and Brn3a 2) or control siRNAs and analysed by immunoblotting 48 h
after transfection. Representative blots (n¼ 3) are shown.
B. Microscopic pictures of 1205Lu melanoma cells 2 or 4 days after transfection of Brn3a-specific siRNAs or control siRNA. Scale bars: 100mm.
C. Different melanoma cell lines, i.e. 1205Lu, WM1158 and WM1232 (high Brn3a levels) and WM3211 (low Brn3a levels), were transfected with siRNAs as
described in (A). Viable melanoma cells were quantified 4 days after siRNA transfection. Viability of cells treated with transfection reagent alone (‘no siRNA’)
was set to 100%. Mean SD is shown. p¼0.003 or less, t-test, n¼3 per group; n.s.: not significant (p> 0.05).
D. 1205Lu melanoma cells were subcutaneously injected into nude mice. Upon palpability of tumours, mice were systemically treated three times per week by
intraperitoneal injection of 10mg of Brn3a-specific or control siRNA complexed with polyethylenimine. Tumour growth in Brn3a siRNA-treated animals was
significantly reduced (p¼0.0078, Wilcoxon matched pair test, n¼5 per group).
E. Brn3a mRNA levels in tumours isolated at day 29. Mean of each group SEM is shown.
922  2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. EMBO Mol Med (2013) 5, 919–934
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and Bcl-2 mRNA levels were indirectly regulated by activated
p53 (see below) as evidenced by co-inhibition studies
(Supporting Information Fig S2C). Similarly, proapoptotic
molecules Bax and Bak were found to be regulated via p53
(Supporting Information Fig S2D).
The tumour suppressor p53 is activated upon Brn3a
inhibition and mediates cell cycle arrest
Immunoblots revealed a strong increase in p53 levels upon Brn3a
inhibition, associated with increased p21, a cell cycle inhibitory
protein and known p53 target gene in melanoma (Besch et al,
2007) (Fig 4A). Increased p53 levels were associated with
increased activity as determined by DNA binding activity
(Supporting Information Fig S3A). p53 accumulated due to
decreased protein turnover (Supporting Information Fig S3B).
Next, the relevance of p53 was tested by blocking p53 activation
in Brn3a-inhibited cells. Co-transfection of 1205Lu cells with
p53- and Brn3a-specific siRNA efficiently abrogated accumula-
tion of p53 and consequently blocked induction of p21 (Fig 4B).
Cell cycle analysis revealed that cell cycle progressionwas clearly
restored when p53 was blocked, indicating that p53 was indeed
responsible for the cell cycle arrest upon Brn3a inhibition (Fig 4C
and Supporting Information Fig S3C).
Loss of Brn3a in melanoma leads to DNA double-strand
breaks and activation of DNA damage signalling
It has been suggested that Brn3a and p53 can interact on the
protein level, thereby antagonizing transcriptional activity of
both molecules (Budhram-Mahadeo et al, 1999a; Hudson et al,
2005; Sugars et al, 2001). Hence Brn3a could be an important
suppressor of p53 in melanoma. However, in melanoma
cells, we could not detect interaction of Brn3a protein with
endogenous p53 in co-immunoprecipitation assays. In addition,
increased p53 protein levels are not expected when p53 is
activated due to release from Brn3a interaction. To explore
alternative mechanisms, we analysed p53 phosphorylation
patterns. p53 phosphorylation at Ser15, but not at Ser46, was
observed upon silencing of Brn3a (Fig 5A), consistent with
activated DNA damage signalling (Shieh et al, 1997). This was
confirmed by increased phosphorylation of Chk2 (Fig 5A) and of
ataxia teleangiectasia mutated (ATM) (Fig 5B). Next, nuclear
Mre11/Rad50-containing foci were analysed, which are formed
on DNA double-strand breaks (Hopfner et al, 2002). A
significant increase (from 5% in controls to 20%) in foci-
containing cells was observed upon Brn3a inhibition (Fig 5C,D).
DNA damage was also confirmed by staining cells for histone
H2A.X phosphorylation in a time course experiment, where
H2A.X phosphorylation became apparent after 48 h (Fig 5E),
coinciding with the onset of cell cycle arrest. Together, the data
demonstrate that loss of Brn3a in melanoma causes DNA
damage that leads to p53 activation.
Brn3a promotes anchorage-independent growth in vitro and
tumour growth in vivo
Altogether, the data demonstrated an essential role of Brn3a in
melanoma cells. We, next, tested the effects of Brn3a in skinEMBO Mol Med (2013) 5, 919–934 cells, which display low Brn3a expression levels (Fig 1A and B).
First, Brn3a was expressed in primary human melanocytes by
lentiviral transduction (Fig 6A). Potential oncogenic properties
of Brn3a were assessed by determining anchorage-independent
growth. Colony formation was significantly enhanced in
melanocytes expressing Brn3a, resulting in a fivefold increased
cell growth in soft agar (Fig 6B). Similar results were achieved
with immortalized melanocytes (Supporting Information Fig
S4). Notably, similar observations weremade in primary human
fibroblasts, which confirms the oncogenic role of Brn3a
irrespective of the cell lineage (Supporting Information Fig
S5A and B). When subcutaneously inoculated into NOD-SCID
mice, these cells did not form tumours indicating that further
factors besides Brn3a are required to convert primary cells into
tumourigenic cells. To further test the role of Brn3a in vivo,
Brn3a was analysed in immortalized NIH3T3 fibroblasts, known
to form tumours solely upon expression of HRAS (Land et al,
1983). HRAS-transformed NIH3T3 fibroblasts formed colonies
in soft agar. Co-expression with Brn3a, however, almost
doubled colony formation and cell growth (Supporting
Information Fig S5C and D). In vivo, tumour growth of
HRAS-transformed NIH3T3 was considerably increased upon
Brn3a expression (Supporting Information Fig S5E). Increased
levels of Brn3a in tumours were confirmed after animals were
sacrificed (Supporting Information Fig S5F). Finally, as a model
more closely related to melanoma, primary human melanocytes
were analysed that had been engineered to become tumouri-
genic by defined genetic modifications, i.e. hTERT, large T
antigen and HRAS (Gupta et al, 2005). Again, Brn3a expression
doubled colony numbers and cell growth in soft agar assays, and
promoted tumour growth in vivo (Fig 6C–F). Together, the data
provide evidence for an oncogenic role of Brn3a, as Brn3a
promotes anchorage-independent growth in vitro and tumour
growth in vivo.
Brn3a cooperates with activated RAS/RAF signalling by
reducing oncogene-induced senescence in melanocytic
tumourigenesis
Brn3a was associated with malignant transformation and may
cooperate with active proliferation drivers common in tumours.
Indeed, Brn3a promoted tumour growth in synthetic tumour
models where RAS signalling is activated (Fig 6C–F, Supporting
Information Fig S5C-F). In primary cells, however, proliferation
drivers such as oncogenic RAS or RAF trigger a permanent cell
cycle arrest termed oncogene-induced senescence, which is
considered to be a cellular defence mechanism that protects
against transformation. Brn3a was detected even in early stage
melanoma cell lines, but not in melanocytes (Fig 1A and B). In
nevi – benign melanocytic tumours – the activating V600EBRAF
point mutation is found in up to 80%. It has been suggested that
a senescence growth arrest is induced in these common
melanocytic lesions thereby preventing progression to malig-
nant melanoma (Michaloglou et al, 2005; Pollock et al, 2003).
Furthermore, there is compelling evidence that expression of
V600EBRAF in primary human melanocytes causes senescence
in vitro (Gray-Schopfer et al, 2006; Michaloglou et al, 2005)
indicating that mutated BRAF alone is not sufficient for2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 923
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924malignant transformation to melanoma. To investigate whether
Brn3a plays a role in the regulation of V600EBRAF-induced
melanocyte senescence and melanomagenesis, we analysed
benign melanocytic nevi for Brn3a expression. Notably, only
3% (1 of 38) stained positive, compared to 55% (49 of 89) in
primary melanoma samples, indicating that Brn3a is a clear
indicator of benign versus malignant lesions (Fig 7A). The low
abundance of Brn3a in nevi led to the suggestion that Brn3a
might be involved in bypassing the V600EBRAF-induced
melanocyte senescence response. DNA double-strand breaks
have been implicated in oncogene-induced senescence (Bart-
kova et al, 2006; Di Micco et al, 2006). Consequently, the DNA
double-strand breaks in Brn3a-inhibited melanoma cells could
potentially reflect oncogene-induced DNA damage that is not
suppressed by Brn3a anymore. Therefore, we expressed Brn3a
alone or together with V600EBRAF in melanocytes (Fig 7B). As
reported in previous studies, V600EBRAF expression led to DNA
damage as determined by histone H2A.X phosphorylation.
Importantly, DNA damage was clearly decreased in the presence
of Brn3a in immortalized (Sviderskaya et al, 2003) or primary
human melanocytes (Fig 7C). Next, the influence of Brn3a on
V600EBRAF-driven senescence was studied in more detail.
Primary humanmelanocytes were engineered to express hTERT
via lentiviral transduction prior to further investigation to avoid
telomere-associated replicative senescence. On day 6 after
transduction with V600EBRAF, the oncogene-induced senescence
phenotype became fully apparent. Increased numbers of
melanocytes displaying increased senescence-associated b-
galactosidase activity, senescence-associated heterochromatin
foci and foci positive for phosphorylated histone H2A.X were
observed (Fig 7D). Consistent with our hypothesis, V600EBRAF-
induced senescence was clearly attenuated when Brn3a was
expressed along with V600EBRAF. The number of b-galactosi-
dase-positive cells was significantly reduced from 79 to 43%.
Similar observations were made when measuring heterochro-
matin foci and DNA damage-associated foci (Fig 7D). To test
whether reduction of senescence markers is indeed associated
with increased cell proliferation, cells were stained for the
proliferation marker Ki67. V600EBRAF transduction strongly
reduced Ki67-positive cells from 37 to 6%. Co-transduction of
V600EBRAF and Brn3a, however, led to a significant increase inFigure 3. Inhibition of Brn3a leads to cell cycle arrest in melanoma cells foll
A. Cell cycle analysis of 1205Lu melanoma cells 24, 48 and 72h after transfection
G2 phase at 48 h and the sub-G1 fraction typical for apoptosis at 72 h. Repre
B. Cell cycle analysis of 1205Lu, WM1158 and WM1232 melanoma cells treated
(black) is shown. Error bars represent SD of cells in G1 phase. p¼0.029 or less co
5 (WM1232); n.s.: not significant (p>0.05).
C. Cell cycle analysis of the cell line WM3211 (low Brn3a levels) as described in
D. Analysis of apoptosis in 1205Lu, WM1158, WM1232 and WM3211 melanoma
positive and propidium iodide-negative cells are depicted. Mean SD is shown
served as positive control for apoptosis induction in WM3211.
E. Analysis of caspase 3, 9 and 8 activation in 1205Lu cells treated as described in
respective active subunits (cleaved). WM9 melanoma cells treated with 1mM
(n¼ 3) are shown.
F. Quantification of antiapoptotic Bcl-2, Bcl-xL and Bcl-w by immunoblotting 3 d
(n¼ 3) are shown.
 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.Ki67-positive cells from 6 to 13% (Fig 7E). When cell
proliferation was measured in a time-course experiment,
V600EBRAF transduction led to a robust cell proliferation stop
that was maintained for at least 12 days. Importantly, Brn3a
transduction partially reverted the V600EBRAF-mediated cell
proliferation stop. The cells started to proliferate, leading to 3-
fold increased cell numbers in V600EBRAF/Brn3a-transduced
cells compared to cells transduced with V600EBRAF (Fig 7F).
Together, the data provide evidence that Brn3a is absent in
senescent nevi, but present inmelanoma. Brn3a cooperates with
active RAS/RAF signalling by attenuating oncogene-induced
DNA damage. Therefore, Brn3a promotes tumourigenesis by
reducing oncogene-induced senescence.DISCUSSION
Melanocytes and neuronal cells originate from the same
precursors in the neural crest. Here, we demonstrate that the
POU domain transcription factor Brn3a, normally expressed in
neural crest cells, is expressed in melanoma. Compared to other
alterations in melanoma, increased Brn3a levels were observed
in melanoma at a high incidence (55%) and in the majority of
melanoma cell lines, but not in melanocytes and nevi. Brn3a is
essential for melanoma cell proliferation and survival: speci-
fically in Brn3a-positive melanoma cells, inhibition of Brn3a
causes DNA double-strand breaks leading to p53-mediated
cell cycle arrest and subsequent apoptosis. In vivo, systemic
targeting of Brn3a reduced growth of subcutaneous melanomas.
Furthermore, gain-of-function experiments in Brn3a-negative
cells revealed an oncogenic role of Brn3a. Two experimental
settings were utilized: In the first setting, Brn3a promoted
anchorage-independent growth of non-malignant cells and
accelerated tumour growth of tumourigenic cells, demonstrat-
ing a general tumour-promoting role of Brn3a. In the second
setting, Brn3a was studied in combination with V600EBRAF, the
most important oncogenic alteration in melanoma, which is
present also in nevi. Here, Brn3a reduced V600EBRAF-induced
senescence. This demonstrates that Brn3a, absent in senescent
nevi but present inmelanoma,may be an important endogenous
suppressor of the V600EBRAF-induced melanocyte senescenceowed by mitochondrial apoptosis.
with Brn3a-specific or control siRNAs. Arrows indicate the loss of cells in S and
sentative histograms (n¼3) are shown.
as described in (A). The mean of cells in G1 (grey), S (white) and G2/M phase
mpared to control siRNA-treated cells, t-test, n¼3 (1205Lu), 4 (WM1158) and
(B).
cells 4 days after transfection of Brn3a-specific or control siRNAs. Annexin V-
. p¼0.022 or less, t-test, n¼ 3 per group. Treatment with staurosporine (STS)
(D) by immunoblotting with antibodies specific for procaspases (pro) and their
staurosporine (STS) for 5 h served as a positive control. Representative blots
ays after transfection of Brn3a-specific or control siRNAs. Representative blots
"
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Figure 3.
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Figure 4. The tumour suppressor p53 is activated upon Brn3a inhibition and mediates cell cycle arrest.
A. Analysis of Brn3a, p53 and p21 by immunoblotting in 1205Lu melanoma cells 48 h after transfection of Brn3a-specific or control siRNAs. Representative blots
(n¼3) are shown.
B. Analysis of Brn3a, p53 and p21 in 1205Lu cells 48 h after co-transfection of Brn3a-specific, p53-specific or control siRNAs. Representative blots (n¼3) are
shown.
C. Cell cycle analysis of 1205Lu cells treated as described in (B). Representative histograms (n¼3) are shown. The percentage of cells in the G1, S and G2/M phase
is indicated in the upper right part of the histogram.
926response and implicates a role of Brn3a in melanocytic
tumourigenesis.
In the neural crest, Brn3a is expressed in precursors that
differentiate into sensory neurons (Greenwood et al, 1999).
Brn3a levels were increased in differentiating cells of the CNS,
but Brn3a is also expressed in undifferentiated cell populations
(Hudson et al, 2004) and in proliferating cells of the PNS
that display mitotic figures (Fedtsova & Turner, 1995). In the
melanocytic lineage, a potential role of Brn3a in development
has not been determined. Similar to neuronal cells, in which
Brn3a expression is terminated in most adult tissues, Brn3a
expression was not observed in melanocytes. There is clear
evidence that Brn3a is important for neuronal survival. Brn3a-
deficient mice experience a massive loss of sensory neurons
during embryogenesis (McEvilly et al, 1996; Xiang et al, 1996).
Nevertheless, re-expression of Brn3a in tumours has been 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.reported rarely, which may be due to its tissue-specific
expression (Collum et al, 1992; Diss et al, 2006; Leblond-
Francillard et al, 1997; Ndisdang et al, 1998). In neuronal cells,
Brn3a can activate transcription of antiapoptotic genes like Bcl-2
or Bcl-xL (Smith et al, 1998, 2001) and enhance apoptosis
resistance (Hudson et al, 2004; Smith et al, 2001). In melanoma
cells, besides cell cycle arrest, loss of Brn3a was associated with
apoptosis and with decreased Bcl-2 and Bcl-xL levels. However,
downregulation of these proteins in response to Brn3a was not
observed on the mRNA level, suggesting that both were not
directly regulated by Brn3a in melanoma.
A well-documented function of Brn3a is antagonizing p53,
which prompted us to study whether Brn3a is a lineage-specific
suppressor of p53 in melanoma. In a neuronal cell line, the
p53-antagonizing effect of Brn3a was reported to be mediated
through protein–protein interactions at the promoter of theEMBO Mol Med (2013) 5, 919–934
www.embomolmed.org Research Article
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Figure 5. Inhibition of Brn3a causes DNA double-strand breaks that lead to activation of p53.
A. Analysis of p53 phosphorylation (Ser15 and Ser46) and of checkpoint kinase 2 (Chk2; Thr68) in 1205Lu melanoma cells by immunoblotting 48 h after
transfection of Brn3a-specific or control siRNA. Representative blots (n¼ 3) are shown.
B. Phosphorylation status of ATM (Ser1981) by ELISA in 1205Lu cells treated as described in (A). Mean SD is shown. p< 0.0009, t-test, n¼ 6 per group.
C. Analysis of Mre11/Rad50-containing enzyme foci, representing active sensing of DNA double-strand breaks, in 1205Lu cells 40 h after transfection of
Brn3a-specific or control siRNA. Immunofluorescence staining of Mre11 (red), Rad50 (green) and of nuclei (Hoechst 33342; blue) is shown. Arrows indicate
nuclei with Mre11/Rad50 foci. Representative results (n¼3) are shown. Scale bar: 50mm.
D. Percentage of cells containing Mre11/Rad50 foci treated as described in (C). Mean SD is shown. p<0.0009, t-test, n¼ 3 per group.
E. Time-course analysis of histone H2A.X phosphorylation. Immunoblots were performed 24, 48, 72 and 96h after Brn3a siRNA transfection. Representative blots
(n¼ 2) are shown.
EMBO Mol Med (2013) 5, 919–934  2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 927
Research Article www.embomolmed.org
Brn3a is required for melanoma survival
Figure 6. Brn3a promotes anchorage-independent growth in vitro and tumour growth in vivo.
A. Brn3a levels in primary human melanocytes after lentiviral transduction of a Brn3a-encoding or an empty vector (control). Mean SD is shown. p¼ 0.023,
t-test, n¼ 3 per group.
B. Left panel: Microscopic quantification of colony formation of primary melanocytes cultured for 11 days in soft agar. Numbers of colonies (>10 cells) are shown
in brackets. p¼ 0.001, t-test, n¼ 3 per group. Right panel: Fluorimetric quantification of cellular DNA of cells cultured for 9 days in soft agar. Mean SD is
shown. p¼0.001, t-test, n¼3 per group.
C. Brn3a levels in tumourigenic Mel-STR melanocytes that were lentivirally transduced with Brn3a-encoding (Brn3a) or empty (control) vectors. Mel-STR
melanocytes are tumourigenic due to defined genetic alterations. Mean SD is shown. p¼0.003, t-test, n¼2 per group.
D. Left panel: Colony formation of Mel-STR melanocytes at day 7. p¼ 0.007, t-test, n¼3 per group. Right panel: Fluorimetric quantification of anchorage-
independent growth. Mean SD is shown. p¼0.009, t-test, n¼ 3 per group.
E. Subcutaneous tumour growth of Brn3a-expressing or control Mel-STR melanocytes. Mean SEM is shown. p< 0.05, t-test, n¼3 per group.
F. Brn3a mRNA levels in tumours at the end of the experiment. Mean SD is shown. p¼0.006, t-test, n¼3 per group.
928respective target gene (Budhram-Mahadeo et al, 1999a; Hudson
et al, 2005). However, in melanoma we did not detect
interaction of Brn3a with p53 in co-immunoprecipitation
experiments. Instead of release of p53 from interaction with
Brn3a, p53 accumulation and DNA damage was observed.
Therefore, our data support a model in which accumulation of
p53 protein is observed as a consequence of activated DNA
damage signalling.
With respect to tumourigenesis, it is attractive to investigate
Brn3a in the context of known oncogenic proliferation 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.pathways. Elevated RAS/RAF signalling due to oncogenic
mutations in BRAF or NRAS is well studied in melanoma,
but these mutations are also common in non-proliferating
senescent nevi (Pollock et al, 2003). In cell culture, expression
of oncogenic BRAF in melanocytes induces senescence
(Michaloglou et al, 2005). Brn3a, however, was very frequently
expressed even in early stage melanoma cell lines, but
absent in nevi and may be important to attenuate BRAF-
induced senescence. Supporting this, a cooperative effect of
Brn3a and RAS in malignant transformation has been shown inEMBO Mol Med (2013) 5, 919–934
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to DNA replication stress have been implicated in oncogene-
induced senescence (Bartkova et al, 2006; Di Micco et al, 2006)
and active RAS/RAF signalling can lead to tumourigenesis
when p53 is inactivated (Dankort et al, 2007; Patton et al, 2005;
Serrano et al, 1997; Yu et al, 2009). Indeed, Brn3a clearly
reduced BRAF-induced DNA damage and senescence in
melanocytes. However, Brn3a was not able to fully revert
V600EBRAF-driven senescence. Other known senescence path-
ways like DNA replication stress or metabolic stress are likely to
be still active. Another reason may be the experimental setting
where V600EBRAF and Brn3a were expressed using the same
promoters. This leads to similar protein amounts, but may lead
to different protein activities, because Brn3a represents the wild-
type form and BRAF the constitutively activated mutated form.
Nevertheless, Brn3a was able to reduce BRAF-induced DNA
damage in normal cells and DNA damage has also been
observed in melanoma cells upon Brn3a inhibition. These cell
lines harbour the V600EBRAF allele and the DNA damage
may reconstitute oncogene-driven DNA damage leading to a
senescence-like phenotype. Together, Brn3a may play a key
role in tumourigenesis by avoiding DNA damage caused by
oncogene-induced stress. The potential roles of Brn3a in
tumourigenesis are summarized in Fig 7G.
The identification of Brn3a in melanoma as a new tumour-
promoting factor may have important impact for clinical
applications. Brn3a may prove useful as a biomarker to
distinguish early stage melanomas from benign lesions and
its potential as a therapeutic target has been demonstrated in
our study. Its tissue-restricted expression profile may allow
therapeutics to target melanoma tissue more selectively.
Chemical compounds, able to compete with Brn3 transcription
factors, may provide the basis for Brn3a-specific inhibitors
(Peixoto et al, 2008). An important issue that we pursue in the
future is the characterization of the molecular mechanisms
by which Brn3a contributes to malignancy. Brn3a and its
associated signalling pathways may offer new approaches for
the understanding of melanocytic transformation and for
therapeutic interventions of this highly therapy-resistant
tumour.MATERIALS AND METHODS
Reagents and antibodies
Anti-caspase 3, anti-caspase 8 (1C12), anti-caspase 9, anti-Bcl-xL,
anti-Bcl-w, anti-phospho-Chk2 (Thr68), anti-phospho p53 (Ser15),
anti-phospho p53 (Ser20), anti-Bak and HRP-conjugated secondary
antibodies were obtained from New England Biolabs (Frankfurt,
Germany), anti-cytochrome c (clone 7H8.2C12) from BD Biosciences
(Heidelberg, Germany), and anti-Brn3a (14A6), anti-Bax (3D2), and
anti-p21 (F-5) from Santa Cruz Biotechnology (Heidelberg, Germany).
Anti-Bcl-2 (Ab-1), anti-p53 (Ab-6) and anti-Mre11 were from Merck
Biosciences (Schwalbach/Ts., Germany), anti-b-actin (AC-15) from
Sigma (Taufkirchen, Germany) and anti-Rad50 (clone 2C6) antibody
was from Millipore (Schwalbach, Germany). Primers and siRNAs were
from MWG Biotech (Ebersberg, Germany).EMBO Mol Med (2013) 5, 919–934 Cell culture
Human melanoma cell lines were a kind gift of Dr. M. Herlyn (Wistar
Institute, Philadelphia, PA, USA) and maintained in a culture medium
consisting of MCDB153 (Sigma) with 20% Leibovitz’s L-15 (PAA
Laboratories, Coelbe, Germany), 2% FBS (PAA Laboratories), 1.68mM
CaCl2 (Sigma) and 5mg/ml insulin (Sigma). For analysis, cells were
detached with 0.2% EDTA in PBS. Keratinocytes, fibroblasts and
melanocytes were isolated from neonatal human foreskins and
cultivated as described (Berking et al, 2001).
Small interfering RNAs
siRNAs were designed as described (Besch et al, 2009). Sequences of
the 19nt sense strand of each siRNA are: Brn3a 1: GCAAGAGCCAUC-
CUUUCAA; Brn3a 2: CCACGUACCACACGAUGAA; AND P53: GUACCAC-
CAUCCACUACAA. Non-silencing control siRNAs were designed to
contain random sequences that do not match within the human
and murine genome. The sequences of control siRNAs were
GCGCAUUCCAGCUUACGUA (named control or control 1) or
GCGCUAUCCAGCUUACGUA (named control 2). siRNAs were trans-
fected at 20 nM with 1.25ml Lipofectamine RNAiMAX. In co-
transfection experiments each siRNA (20nM) was complexed sepa-
rately to 1.25ml Lipofectamine RNAiMAX.
RNA extraction and quantification
Total RNA was extracted from cells using Trizol (Invitrogen) and
analysed by quantitative RT-PCR. One microgram of RNA was reverse
transcribed using Expand Reverse Transcriptase (Roche Diagnostics,
Mannheim, Germany) and poly(dT) oligonucleotide (Roche Diagnos-
tics). Quantitative PCR for Brn3a mRNA shown in Fig 1A was
performed using the FastStart SYBR Green Master Kit (Roche
Diagnostics). Specific amplification was controlled by melting curve
analysis, gel electrophoresis, and additionally by sequencing of the
PCR product. All other qPCRs were carried out using the LightCycler
TaqMan Master Kit (Roche Diagnostics) together with the Universal
ProbeLibrary system (Roche Diagnostics). Relative gene expression was
expressed as a ratio of the expression level of the gene of interest to
that of hypoxanthine phosphoribosyltransferase (HPRT) RNA deter-
mined in the same sample.
Protein preparation and analysis
Adherent and supernatant cells were lysed in 50mM Tris; pH 7.4,
0.25M NaCl, 1mM EDTA, 0.1% Triton X-100, 0.1mM EGTA, 5mM
Na3VO4, 50mM NaF and protease inhibitors (Complete, Mini, EDTA-
free, Roche Diagnostics). Lysates were analysed by enzyme-linked
immunosorbent assay (ELISA) for ATM activity (R&D Systems,
Wiesbaden-Nordenstadt, Germany) or by immunoblotting as de-
scribed (Besch et al, 2009). Protein levels of b-actin were analysed as a
control for constant loading and transfer. In Brn3a immunoblots using
anti-Brn3a (14A6) antibody, PVDF membranes were denatured after
protein transfer by incubating in a dilution series of 4, 2, 1, 0.5 and
0.25M guanidine thiocyanate (Sigma) in 0.1% Tween 20 in PBS,
followed by 10min washing in 0.1% Tween 20 in PBS. Membranes
were then blocked and further treated as described above.
Gene reporter analysis
Brn3a transcriptional activity was tested using a firefly luciferase
reporter plasmid (pGL2-Brn3a), kindly provided by Dr. E. Turner,2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 929
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930University of California at San Diego, USA. It contains three
consecutive Brn3a consensus binding sites linked to a prolactin
minimal promoter (Gruber et al, 1997). Cells were transfected in 96-
well dishes using FuGENE6 (Promega) with 50 ng of the reporter
plasmid and 50ng of a Renilla-Luc-expressing plasmid (phRLTK;
Promega). Luciferase activity was measured according to the
manufacturer’s protocol (Promega). Luciferase activity values were
normalized to Renilla activity of the same extract.
Immunocytochemistry
Cells were fixed in room temperature with 4% paraformaldehyde in
PBS for 20min, permeabilized with 0.1% Triton X-100 (Sigma) in PBS
for 20min, and blocked with 5% BSA in PBS for 2 h. For analysis of
Mre11/Rad50 foci, cells were then incubated with anti-Rad50
(1:1000) and anti-Mre11 (1:100) antibodies overnight at 48C. For
Brn3a analysis cells were incubated with anti-Brn3a (Biomol; 1:1000).
After washing with 1% BSA in PBS, cells were incubated with
fluorescence-labelled secondary antibodies (Alexa Fluor 488 Goat
anti-mouse SFX (Invitrogen); NorthernLights Anti-rabbit IgG-NL557
(R&D Systems); both 1:250) for 2 h at room temperature. Cells were
covered with Gel/Mount (Biomeda, Foster City, USA) and analysed
using a Zeiss Axioskop (Zeiss, Munich) with Axiovision software.
Mre11/Rad50-foci displaying cells were quantified by counting
approximately 4500 cells per condition.
Immunohistochemistry
Histopathologically confirmed tissue samples of primary melanomas
and melanocytic nevi were collected at the Department of Dermatol-
ogy at the Ludwig-Maximilian University of Munich. Informed consent
was obtained from all patients and the experiments conformed to the
principles set out in the WMA Declaration of Helsinki. Paraffin-
embedded sections were deparaffinized in xylene and rehydrated in a
graded series of isopropanol. Antigen retrieval was achieved by
microwave in citrate puffer, pH 6.0 (Chemicon ICH Select, Temecula,
Canada). Blocking of unspecific binding was performed with FCS/TRIS
20%. The primary antibody was a monoclonal rabbit IgG anti-human
Brn3a (clone EP1972Y, Biomol, Hamburg, Germany) at a dilution of
1:50; the negative control was a normal rabbit IgG. Secondary
antibodies were mouse anti-rabbit antibody (M0737, DAKO, Glostrup,Figure 7. Brn3a reduces oncogene-induced senescence in melanocytes.
A. Thirty-eight specimens of human melanocytic nevi were analysed for Brn3a exp
for Brn3a (upper panel) or the melanocyte marker Melan A (lower panel) are s
cohort. Scale bar: 200mm. The lower-right insert depicts a fourfold magnifica
B. Expression of Brn3a (left panel) and V600EBRAF (right panel) in immortalized (p1
an empty vector (control), Brn3a-encoding vector (Brn3a), or co-transduced wit
p¼ 0.012 or less, t-test, n¼2 per group.
C. Analysis of DNA damage by immunoblotting of phosphorylated histone H2A.X in
or primary human melanocytes (lower panel). Representative blots (n¼ 3) ar
D. Primary human melanocytes were transduced with empty vector (control), V600
day 6 for the appearance of markers indicative for senescence: b-galactosidas
Heterochromatin foci (DAPI) and phosphorylated H2A.X foci (phos-H2A.X) were
shown. Scale bar: 10mm. Right panel: Mean percentage of cells displaying incre
heterochromatin foci (p<0.003, t-test, n¼4 per group), or containing phos
E. Percentage of Ki67-positive melanocytes that were treated as described in (D
F. Primary melanocytes transduced as described in (D). Two days after transductio
at day 3, 6, 9 and 12 after seeding. Mean SD is shown. p¼ 0.002 or less, t
G. Summary of the potential role of Brn3a in tumourigenesis of melanoma with
 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.Denmark) and rabbit anti-mouse antibody (Z0259, DAKO) combined
with alkaline phosphatase anti-alkaline phosphatase (APAAP) immu-
nocomplex (D0651, DAKO), i.e. soluble immunocomplexes prepared
from calf intestinal alkaline phosphatase and monoclonal mouse
antibody to calf intestinal alkaline phosphatase. Fast red (Sigma-
Aldrich, Steinheim, Germany) was used as substrate and Mayer’s
haematoxylin as counterstaining. The sections were mounted in
Kaiser’s glycerol gelatine. Nerve fibres and smooth muscle cells stained
positive for Brn3a and, therefore, served as internal positive control for
successful staining. Tissue sections were inspected by two investiga-
tors (CB, RB).
Quantification of viable cells
Viable cells were quantified in 12-well dishes utilizing a fluorimetric
assay (CellTiter-Blue Cell Viability Assay, Promega, Mannheim,
Germany). Viable cells with intact metabolism are determined by
their ability to reduce cell-permeable resazurin to fluorescent
resorufin. Medium was replaced with 375ml of culture medium and
75ml of CellTiter-Blue reagent. After 1 h incubation at 378C
fluorescence was measured.
Cell cycle analysis
Cells were fixed in 70% ice-cold ethanol. RNA was degraded by
digestion with 100mg/ml RNAse A (Sigma) at 378C for 15min. Cellular
DNA was then stained with 50mg/ml propidium iodide (Sigma) and
analysed by flow cytometry and ModFit LT software (Verity Software,
Topsham, USA).
Quantification of apoptotic cells and cell death
Adherent and supernatant cells were analysed by staining with FITC-
labelled Annexin V (Roche Diagnostics) and propidium iodide (Sigma).
Annexin V staining was performed according to the manufacturer’s
instructions. Propidium iodide was added to a final concentration of
0.5mg/ml. Cells were analysed by flow cytometry and CellQuest
software (Becton Dickinson, Heidelberg, Germany).
p53 activity
p53 activity was measured by its DNA binding capacity using an ELISA
system (TransAm ELISA; Active Motif, Carlsbad, USA). Nuclear proteinression in situ by immunohistochemistry. Two representative samples stained
hown. Nevus 3 (right panel) represents the Brn3a-positive nevus found in this
tion of the respective area.
6 null, hTERT overexpressing) human melanocytes that were transduced with
h V600EBRAF- and Brn3a-encoding vectors (Brn3aþBRAF). Mean SD is shown.
Brn3a-, V600EBRAF- or Brn3a/V600EBRAF-expressing immortalized (upper panel)
e shown.
EBRAF alone (BRAF), or V600EBRAF together with Brn3a. Cells were analysed at
e activity (b-gal) was visualized by light microscopy (LM). Scale bar: 100mm.
assessed by immunofluorescence microscopy. Representative cell nuclei are
ased b-galactosidase activity (p<0.0009, t-test, n¼ 4 per group), containing
-H2A.X foci (p<0.014, t-test, n¼2 per group). Mean SD is shown.
). Mean SD is shown. p¼0.026, t-test, n¼4 per group.
n, 50,000 cells were seeded (day 0). Cell number was determined by counting
-test, n¼3 per group.
respect to known oncogenic insults.
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The paper explained
PROBLEM:
Melanoma belongs to the most deadly types of skin cancers and
arises from melanocytes, the pigment cells of the skin. Recently
developed therapies are typically based on targeting the MAP
kinase pathway, which is activated in melanoma due to
mutations in BRAF or NRAS. These therapies display unprece-
dented response rates, but they are characterized by frequent
resistance and they are available only for a subset of patients.
Therefore, alternative approaches are needed to improve therapy
options for melanoma patients.
RESULTS:
A common observation is that molecules involved in embry-
ogenesis can be expressed in cancer cells which may be a way to
acquire malignant properties. During embryogenesis, pigment
cells and neuronal cells both derive from the neural crest. In this
study, we screened for neural crest molecules in melanoma and
identify the neural crest transcription factor Brn3a being highly
expressed in melanoma, but not in melanocytes and benign
melanocytic tumours. Inhibition of Brn3a causes DNA damage
that leads to cell cycle arrest and apoptosis in melanoma cell
lines and reduces tumour growth in mice. Furthermore, the
oncogenic property of Brn3a is analysed. Brn3a promotes
anchorage-independent growth of melanocytes, increases
tumour growth of tumourigenic melanocytes and cooperates
with mutated BRAF to avoid oncogene-induced senescence.
IMPACT:
The study identifies a new factor in melanoma that is frequently
expressed and important for melanoma survival. Due to this
essential role, Brn3a and Brn3a-regulated genes represent
potential new targets for therapy. The cooperation of Brn3a with
oncogenic BRAF points toward a critical role in tumourigenesis.
BRAF mutations are also common in benign tumours in which
Brn3a is absent and, therefore, Brn3a may represent an
important second oncogenic insult required for malignant
melanocytic transformation.
932extracts were prepared using the Nuclear Extract Kit (Active Motif).
Briefly, cells were incubated in a hypotonic buffer for 15min on ice.
Then, detergent was added and nuclei were collected by centrifuga-
tion (14,000 rpm, 48C, 30 s). Proteins were isolated from nuclei as
described in the manufacturer’s protocol.
Tumour engraftment and RNA treatment in vivo
PEI F25-LMW/siRNA complexes were prepared essentially as described
(Werth et al, 2006). Briefly, 54 nmol (720mg) of siRNA were dissolved
in 4835ml 10mM HEPES, 150mM NaCl, pH 7.4, and incubated for
10min. 590ml PEI F25-LMW (6.1mg/ml) were dissolved in 4835ml of
the same buffer, and after 10min pipetted to the siRNA solution and
incubated for 1 h. The mixture was then aliquotted and stored frozen
in 150ml aliquots. Prior to use, aliquots were thawed and incubated
for 1 h at room temperature. One aliquot (150ml containing 10mg
complexed siRNA) was used per injection. 1205Lu cells (3106) in
150ml PBS were injected subcutaneously into both flanks of athymic
nude mice (nu/nu). When solid tumours were established after 13
days, mice were randomized into treatment groups. Treatment was
performed by intraperitoneal injection of 0.77 nmol (10mg) of PEI
F25-LMW-complexed Brn3a-specific siRNA (Brn3a 2) or PEI-com-
plexed control siRNA. Tumour volumes were monitored at each
treatment (see figure). Eighteen hours after the last treatment mice
were sacrificed and tumours removed and immediately snap-frozen.
Tumours were homogenized in 1ml Trizol and RNA was prepared as
described above. Animal studies were performed according to the
national regulations and approved by the Animal Care and use
committee of the Regierungspra¨sidium Giessen or the Regierung von
Oberbayern. All efforts were made to minimize the number of animals
and their suffering. 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.Lentiviral transduction of cells
Brn3a was cloned into modified pLenti6 vectors (Invitrogen). Lentiviral
particles were generated in 293FT cells with the Virapower packaging
system (Invitrogen). Supernatant lentiviruses were concentrated using
Amicon-Ultra 100 kDa filters (Millipore). Cells were infected by a 1.25-
fold concentrated virus supernatant and selected with Blasticidin. In
senescence assays, melanocytes were transduced with Brn3a-encod-
ing and V600EBRAF-encoding lentiviruses and selected with Blasticidin.
V600EBRAF transduction efficiency was controlled by fluorescence
microscopy analysing co-expression of GFP which was consistently
above 90% (data not shown).
Quantification of anchorage-independent growth
Anchorage-independent growth was assessed by cultivation of the
cells in soft agar utilizing the CytoSelect Transformation Assay (BioCat,
Heidelberg). Cells (5103) were seeded into soft agar according to the
manufacturer’s protocol and cultivated for 7–11 days. Colonies (>10
cells) were determined microscopically and quantified by counting.
Cell growth was determined by quantifying the cells fluorimetrically
by staining cellular nucleic acids with CyQuant GR.
Analysis of senescence-associated b-galactosidase activity
Cells were fixed with 2% formaldehyde, 0.2% glutaraldehyde in PBS
for 5min at room temperature, washed with PBS and incubated at
37 8C for fourteen hours with the following senescence-associated
b-gal stain solution containing 1mg/ml 5-bromo-4-chloro-3-indo-
lyl-b-D-galactoside (X-gal): 40mM citric acid/sodium phosphate
(pH 6.0), 150mM NaCl, 2mM MgCl2, 5mM potassium ferrocyanide.
Cells were then washed with PBS and analysed under a light
microscope.EMBO Mol Med (2013) 5, 919–934
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Unless indicated otherwise, Student’s t-test was used to assess the
significance of mean differences. Differences were considered sig-
nificant at a p-value of 0.05 or less, two-tailed.Author contributions
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